Community Acquired Pneumonia (CAP) has a high mortality rate. A new study evaluates the use of hydrocortisone for severe CAP in the ICU setting. Join host, Geoff Wall, as he evaluates if the evidence stacks up.The GameChangerThe use of steroids to treat severe pneumonia has waxed and waned for many years with insufficient evidence. A recent study found steroids improved a number of outcomes, including mortality.Show Segments00:00 - Introductions01:19 - Past Studies on CAP Treatment03:32 - The CAPE Code Study17:05 - The GameChanger: The Study Findings24:31 - Connecting to Practice: Study Limitations26:01 - Closing RemarksHostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthReferences and ResourcesHydrocortisone in Severe Community-Acquired PneumoniaRedeem your CPE hereCPE (Pharmacist)Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)Pharmacists: Get a membershipCE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the past history of major mortality studies for CAP pharmacotherapy2. Discuss the CAPE Code study and its possible implications in the ICU0.05 CEU/0.5 HrUAN: 0107-0000-23-147-H01-PInitial release date: 04/24/2023Expiration date: 04/24/2024Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Ver todos los episodios